answer text |
<p>The National Institute for Health and Care Excellence (NICE) makes recommendations
on whether all new licensed medicines should be routinely funded by the National Health
Service, based on an assessment of their costs and benefits.</p><p>On 27 March 2024,
NICE published final technology appraisal guidance recommending ritlecitinib (Litfulo)
for treating severe alopecia areata in people 12 years old and over. The NHS in England
is legally required to fund medicines recommended by NICE within three months of the
publication of its final guidance.</p>
|
|